O Brien Greene & Co. Inc grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 18.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,610 shares of the biopharmaceutical company’s stock after acquiring an additional 1,200 shares during the quarter. O Brien Greene & Co. Inc’s holdings in Bristol-Myers Squibb were worth $480,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently modified their holdings of the company. Retirement Group LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $27,000. Orion Capital Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $28,000. Perennial Advisors LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $29,000. Brand Asset Management Group Inc. bought a new stake in Bristol-Myers Squibb during the first quarter worth $31,000. Finally, Alpha DNA Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $33,000. 71.75% of the stock is currently owned by institutional investors.
BMY has been the subject of a number of recent analyst reports. Truist Financial raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, April 13th. TheStreet raised Bristol-Myers Squibb from a “c” rating to a “b” rating in a research report on Thursday, April 29th. Truist Securities upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price target for the stock from $66.00 to $74.00 in a report on Tuesday, April 13th. Truist raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, April 13th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $62.00 target price on shares of Bristol-Myers Squibb in a research note on Thursday, May 6th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Buy” and an average target price of $72.36.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Wednesday, April 28th. The biopharmaceutical company reported $1.74 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.82 by ($0.08). The business had revenue of $11.07 billion for the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a negative net margin of 14.53% and a positive return on equity of 33.76%. Bristol-Myers Squibb’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 EPS. Equities analysts anticipate that Bristol-Myers Squibb will post 7.45 EPS for the current fiscal year.
In related news, SVP Adam Dubow sold 3,119 shares of the firm’s stock in a transaction that occurred on Wednesday, May 5th. The shares were sold at an average price of $64.21, for a total value of $200,270.99. Following the sale, the senior vice president now directly owns 16,243 shares of the company’s stock, valued at $1,042,963.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Rupert Vessey sold 30,546 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, May 5th. The shares were sold at an average price of $64.29, for a total transaction of $1,963,802.34. Following the sale, the executive vice president now owns 45,139 shares of the company’s stock, valued at $2,901,986.31. The disclosure for this sale can be found here. In the last quarter, insiders have sold 74,783 shares of company stock valued at $4,770,493. Corporate insiders own 0.11% of the company’s stock.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.